A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth.
Cancer Gene Ther
; 5(4): 207-14, 1998.
Article
in En
| MEDLINE
| ID: mdl-9694072
ABSTRACT
As a prelude to considering retinoblastoma (RB) gene therapy for cancer, a series of human tumor cell lines with either full-length, mutated, or undetectable RB protein were treated with recombinant adenovirus encoding RB (ACNRB). Both RB protein expression and the cytotoxic and antiproliferative effects of ACNRB treatment were evaluated. While the transgene expression of a reporter virus encoding the beta-galactosidase enzyme (rAd-beta-gal) varied among cell lines, the reintroduction and expression of the RB gene resulted in a pronounced inhibition of cellular proliferation in RB-altered cell lines. An antiproliferative response was observed with control adenovirus treatment in some cell lines. ACNRB treatment did not cause detectable cytotoxicity in either RB+ or RB-altered cells. Dose-dependent cytostasis was observed in RB- cell lines. In vivo tumor suppression was observed in a breast xenograft model subsequent to the treatment of established tumors with ACNRB. These data support a role for RB gene therapy of tumors with RB mutations and provide a basis for the further evaluation of ACNRB gene therapy of human cancer.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Retinoblastoma
/
Genetic Therapy
/
Adenoviridae
/
Genetic Vectors
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Cancer Gene Ther
Journal subject:
GENETICA MEDICA
/
NEOPLASIAS
/
TERAPEUTICA
Year:
1998
Type:
Article
Affiliation country:
United States